Gain Therapeutics (NASDAQ:GANX) Announces Quarterly Earnings Results

Gain Therapeutics (NASDAQ:GANX) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06, Zacks reports.

Gain Therapeutics Stock Performance

GANX stock traded up $0.04 during trading hours on Tuesday, reaching $1.12. The stock had a trading volume of 147,911 shares, compared to its average volume of 710,129. The stock has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $1.83. The stock has a market capitalization of $49.09 million, a PE ratio of -2.25 and a beta of 0.29. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. Gain Therapeutics has a fifty-two week low of $0.94 and a fifty-two week high of $4.34.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on GANX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday, October 5th. Finally, BTIG Research restated a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Gain Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

About Gain Therapeutics

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.